重组人血管内皮抑制素联合NP化疗对Ⅳ期非小细胞肺癌患者无进展生存期的影响  

Effect of Recombinant Human Endostatin Combined with NP Chemotherapy on Progression-free Survival of Patients with Stage Ⅳ Non-small Cell Lung Cancer

作　　者：荆璟 张清恒 JING Jin;ZHANG Qingheng(Central Hospital of Luohe,Luohe,462000)

机构地区：[1]河南省漯河市中心医院,462000

出　　处：《实用癌症杂志》2022年第6期922-925,974,共5页The Practical Journal of Cancer

摘　　要：目的 探讨重组人血管内皮抑制素注射液联合NP方案(长春瑞滨+顺铂)治疗Ⅳ期非小细胞肺癌(NSCLC)患者的效果。方法 选取Ⅳ期NSCLC患者80例作为研究对象,依据随机数字表法分为NP组、联合组,各40例。NP组采用NP方案治疗,联合组在NP组基础上采用重组人血管内皮抑制素注射液治疗。比较两组疗效、治疗前、治疗3个疗程后肿瘤标志物[血清血管内皮生长因子(VEGF)、癌胚抗原(CEA)、糖类抗原125(CA125)]水平、循环内皮细胞[外周血活性循环内皮细胞(a CECs)、循环内皮细胞(CECs)]水平、中位无进展生存期、不良反应(恶心呕吐、肝肾功能损伤、粒细胞减少、贫血等)发生率。结果 联合组治疗总有效率(47.50%)(19/40)高于NP组(25.00%)(10/40),中位无进展生存期长于NP组(P<0.05);治疗3个疗程后,两组血清VEGF、CEA、CA125水平均下降,联合组低于NP组(P<0.05);治疗3个疗程后,联合组外周血a CECs、CECs水平下降(P<0.05),NP组无明显变化(P>0.05),联合组低于NP组(P<0.05);两组恶心呕吐、肝肾功能损伤、粒细胞减少、贫血等不良反应发生率比较无明显差异(P>0.05)。结论 重组人血管内皮抑制素注射液联合NP方案治疗Ⅳ期NSCLC患者疗效显著,可改善肿瘤标志物与循环内皮细胞水平,延长无进展生存期,且安全性高。Objective To investigate the effect of recombinant human endostatin injection combined with NP regimen(vinorelbine + cisplatin) in the treatment of patients with stage Ⅳ non-small cell lung cancer(NSCLC).Methods A total of 80 patients with stage Ⅳ NSCLC were selected as the research subjects.According to the random number table method,they were divided into the NP group and the combined group,with 40 cases in each group.The NP group was treated with NP regimen,and the combination group was treated with recombinant human endostatin injection on the basis of the NP group.The curative effect,tumor markers [serum vascular endothelial growth factor(VEGF),carcinoembryonic antigen(CEA),carbohydrate antigen 125(CA125)] levels,circulating endothelial cells [peripheral blood activity] were compared between the two groups before treatment and after 3 courses of treatment.Circulating endothelial cells(a CECs),circulating endothelial cells(CECs) levels,median progression-free survival,incidence of adverse reactions(nausea and vomiting,liver and kidney damage,neutropenia,anemia,etc.).Results The total effective rate(47.50%)(19/40) of the combined group was higher than that of the NP group(25.00%)(10/40),and the median progression-free survival was longer than that of the NP group(P<0.05).,the serum levels of VEGF,CEA and CA125 in the 2 groups were decreased,and the combination group was lower than the NP group(P<0.05).Significant changes(P>0.05),the combination group was lower than the NP group(P<0.05);there was no significant difference in the incidence of adverse reactions such as nausea and vomiting,liver and kidney function damage,granulocytopenia,anemia between the two groups(P>0.05).Conclusion Recombinant human endostatin injection combined with NP regimen is effective in the treatment of stage Ⅳ NSCLC patients.It can improve tumor markers and circulating endothelial cell levels,prolong progression-free survival,and has high safety.

关 键 词：重组人血管内皮抑制素注射液 NP方案 Ⅳ期 非小细胞肺癌 肿瘤标志物 循环内皮细胞 无进展生存期 

分 类 号：R734.2[医药卫生—肿瘤]